Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Astellas, AVEO announce results of tivozanib and sorafenib comparison trial on RCC

AVEO Pharmaceuticals, Inc. and Astellas Pharma Inc. today announced that tivozanib demonstrated superiority over sorafenib in the primary endpoint of progression-free survival (PFS) in TIVO-1, a global, randomized Phase 3 clinical trial evaluating the efficacy and safety of investigational drug tivozanib compared to sorafenib in 517 patients with advanced renal cell carcinoma.

3 Jan 2012

Racial disparities in stage-specific colorectal cancer mortality rates

A new study finds that while colorectal cancer mortality rates dropped in the most recent two decades for every stage in both African Americans and whites, the decreases were smaller for African Americans, particularly for distant stage disease.

23 Dec 2011

AVEO initiates enrollment in tivozanib and mFOLFOX6 Phase 2 combination trial for CRC

AVEO Pharmaceuticals, Inc. today announced the initiation of patient enrollment in an open-label, multicenter, randomized Phase 2 clinical trial, called BATON-CRC, evaluating tivozanib in combination with modified FOLFOX6 (mFOLFOX6) compared to bevacizumab in combination with mFOLFOX6 as first-line therapy in patients with advanced metastatic colorectal cancer.

22 Dec 2011

Combination of bevacizumab and chemoradiation safe, effective for nasopharyngeal carcinoma

The trial conducted by the Radiation Therapy Oncology Group (RTOG) shows the feasibility to deliver bevacizumab to the current chemoradiation standard without any apparent increased adverse side effects.

17 Dec 2011

Researchers identify gene responsible for EMT transformation

Researchers at the Institute for Research in Biomedicine (IRB Barcelona) have identified the gene GATA 6 as responsible for epithelial cells -which group together and are static- losing adhesion and moving towards a new site.

16 Dec 2011

Simple online calculator can tackle pancreatic and bowel cancer

A simple online calculator could offer family GPs a powerful new tool in tackling two of the most deadly forms of cancer, say researchers.

15 Dec 2011

DCC gene protects mice from onset of colon cancer

The research team at Lyon has developed an animal model carrying a mutation of the DCC gene. Mice carrying the mutation develop tumours, because this gene can no longer induce the death of the cancer cells. This discovery could lead to the development of a new targeted cancer treatment that aims to reactivate the dying of cancer cells.

15 Dec 2011

Cancer screening: Is it necessary in the elderly?

There is a long ongoing debate on whether the elderly need to be routinely screened for cancers. A new survey shows that the majority of nearly 19 million Americans over age 75 dutifully get screened for breast, prostate, and colon cancers each year.

14 Dec 2011

Exact Sciences completes underwritten public offering of common stock

Exact Sciences Corp. today announced that it has completed its previously announced underwritten public offering of its common stock at a price of $8.00 per share to the public.

12 Dec 2011

Adjuvant zoledronic acid shows promise against ER-positive premenopausal breast cancer

Researchers have proven the continuing effectiveness of treating patients with estrogen receptor-positive premenopausal breast cancer with adjuvant zoledronic acid in addition to adjuvant endocrine treatment including ovarian function suppression.

8 Dec 2011

Pretreatment fasting glucose could block breast cancer progression

An increasing understanding of molecular pathways that regulate breast and colorectal cancer development and progression has produced new therapeutic agents, including the biologic agents trastuzumab, bevacizumab, and cetuximab. Identifying the indicators that are likely to predict which patients will achieve the best response to these agents represents a major challenge for contemporary oncologists.

7 Dec 2011

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis Pharmaceuticals Corporation will showcase more than one hundred and sixty presentations on data from its robust oncology portfolio at two key medical congresses this month, demonstrating significant advances for patients with cancers and hematological diseases.

3 Dec 2011

Study identifies sulfomucins as potential targets for therapies to treat chronic intestinal inflammatory disorders

In a paper published in the December 2011 issue of Experimental Biology and Medicine, a team of scientists at the University of Illinois, Urbana-Champaign led by Rex Gaskins, PhD have demonstrated that both microbial and host inflammatory factors modulate sulfomucin production in a human cell line, LS174T, that models intestinal goblet cells.

3 Dec 2011

Cancer researchers create catalog of possible targets for new treatments

As cancer researchers continue to identify genetic mutations driving different cancer subtypes, they are also creating a catalog of possible targets for new treatments.

1 Dec 2011

Idera regains global rights to IMO-2055 from Merck KGaA for treatment of cancer

Idera Pharmaceuticals, Inc. today announced that it has regained global rights to IMO-2055, an agonist of Toll-like Receptor (TLR) 9, as part of an agreed-upon termination of its oncology collaboration with Merck KGaA, Darmstadt, Germany.

1 Dec 2011

Oral ingestion of apple polyphenols can prevent colitis in mice

Here's another reason why "an apple a day keeps the doctor away"-according to new research findings published in the Journal of Leukocyte Biology, oral ingestion of apple polyphenols can suppress T cell activation to prevent colitis in mice.

1 Dec 2011

Neogenix novel antibody selected as one of Windhover's 2011 Top 10 Projects to Watch

Neogenix Oncology, Inc. has announced that the company's novel antibody NEO-101, which targets pancreatic and colorectal cancer cells, has been selected as one of Windhover's 2011 Top 10 Projects to Watch.

30 Nov 2011

Elevated blood sugar levels linked with increased risk of colorectal cancer

Elevated blood sugar levels are associated with an increased risk of colorectal cancer, according to a study led by researchers at Albert Einstein College of Medicine of Yeshiva University.

30 Nov 2011

IsoRay initiates shipment of GliaSite radiation therapy system

IsoRay, Inc. announced today it has shipped its first GliaSite radiation therapy system. The Company initiated sales after receiving final approval this week from the State of Washington Department of Health to manufacture its GliaSite radiation therapy system.

28 Nov 2011

OECD report finds U.S. pays more by far for health care

The U.S. healthcare system is more effective at delivering high costs than quality care, according to a new study that found first-rate treatment for cancer but insufficient primary care for other ailments. The study, released on Wednesday by the 34-nation Organization for Economic Cooperation and Development, or OECD, said Americans pay more than $7,900 per person for healthcare each year -- far more than any other OECD country -- but still die earlier than their peers in the industrialized world.

24 Nov 2011